Biogen inc. (BIIB)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10Jun'10Mar'10Dec'09Sep'09Jun'09Mar'09Sep'08
Total revenues

3,534

3,671

3,600

3,616

3,489

3,526

3,439

3,356

3,131

3,307

3,077

3,078

2,810

2,872

2,955

2,894

2,726

2,839

2,777

2,591

2,555

2,640

2,511

2,421

2,129

1,965

1,827

1,723

1,415

1,417

1,385

1,420

1,292

1,326

1,309

1,208

1,203

1,219

1,175

1,212

1,108

1,127

1,120

1,093

1,036

1,092

Cost and expenses:
Cost of sales, excluding amortization and impairment of acquired intangible assets

454

447

430

476

602

488

460

421

446

509

370

366

384

378

416

370

313

331

310

286

312

297

302

291

279

258

234

230

133

133

139

139

133

139

123

100

103

100

95

106

97

99

93

90

98

107

Research and development

476

691

540

484

563

611

507

981

496

587

446

796

423

533

529

473

437

541

519

490

460

500

417

447

528

422

410

327

284

345

304

329

355

338

301

285

293

290

319

331

307

283

304

416

279

268

Selling, general and administrative

570

664

554

587

567

591

497

516

501

572

433

429

498

494

462

492

497

583

477

491

560

573

570

576

511

522

405

431

352

375

299

301

300

283

261

266

244

276

244

262

248

241

226

220

221

232

Amortization and impairment of acquired intangible assets

71

67

283

70

68

254

281

107

103

139

108

117

448

104

99

92

88

96

98

92

95

107

122

116

143

109

99

82

51

50

53

52

45

50

49

55

53

53

53

53

48

55

51

93

89

94

Collaboration profit (loss) sharing

71

59

60

63

58

55

47

39

42

29

35

26

20

11

4

-5

0

-

0

0

-

-

-

-

-

0

0

0

85

77

75

78

85

73

81

88

74

67

63

62

63

63

60

49

42

43

Loss on divestiture of Hillerød, Denmark manufacturing operations

0

-

-17

-2

-

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

(Gain) loss on fair value remeasurement of contingent consideration

4

-2

57

20

-11

-79

87

-1

5

-1

-30

-21

-10

4

-5

-10

-2

-24

-0

2

-7

-7

49

-4

0

-2

0

5

-2

-6

-9

-12

1

-41

2

2

1

-

-

-

-

-

-

-

-

-

Restructuring charges

0

0

0

0

0

2

6

1

1

0

0

0

0

11

11

0

9

93

0

0

0

-

-

-

-

-

-

-

-

0

0

1

0

0

1

0

16

-

-

-

-

-

-

-

-

-

Acquired in-process research and development

75

0

0

0

0

0

27

75

10

0

0

120

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

205

0

39

-

-

-

-

0

Total cost and expenses

1,714

1,893

1,793

1,660

1,987

2,083

1,741

2,143

1,596

1,840

1,423

1,877

1,786

1,984

1,530

1,433

1,348

1,671

1,406

1,358

1,437

1,485

1,363

1,436

1,462

1,315

1,150

1,066

909

987

882

915

922

917

821

797

787

863

981

816

805

743

736

870

731

747

Gain on sale of rights

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4

4

3

3

7

6

5

5

15

31

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

Income from operations

1,819

1,777

1,806

1,955

1,502

1,443

1,697

1,213

1,534

1,466

1,653

1,201

1,024

887

1,425

1,460

1,378

1,168

1,371

1,233

1,117

1,159

1,152

988

671

657

684

662

510

445

535

505

369

409

488

410

416

355

194

395

303

383

384

222

304

345

Other income (expense), net

-120

-49

-27

-197

357

-28

115

-34

-41

-66

-44

-68

-38

-49

-58

-58

-52

-82

-15

-10

-15

-8

-16

4

-5

-5

-4

-10

-14

-14

-4

2

15

-3

-7

-11

9

-4

-6

1

-8

6

9

14

6

-23

Income before income tax expense and equity in loss of investee, net of tax

1,699

1,728

1,779

1,758

1,860

1,414

1,812

1,178

1,493

1,399

1,609

1,132

986

838

1,367

1,402

1,325

1,085

1,356

1,222

1,102

1,150

1,136

993

665

652

679

652

496

431

530

508

384

405

480

399

426

350

187

396

295

389

393

237

311

322

Income tax expense

292

276

211

248

422

469

369

263

322

1,566

383

269

239

190

337

353

356

257

330

292

281

268

274

268

178

190

186

159

65

136

131

121

82

104

127

95

117

78

75

102

75

83

113

92

65

114

Equity in loss of investee, net of tax

-14

-12

-21

-16

-28

0

0

0

0

0

0

0

0

0

0

0

0

0

-6

-4

-0

-0

-5

-1

-7

-4

-6

-2

-3

-2

-1

-0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

Net income

1,392

1,439

1,545

1,494

1,408

944

1,442

915

1,171

-166

1,226

862

747

647

1,030

1,048

969

828

1,019

924

820

882

856

723

479

457

487

490

426

292

398

387

302

300

353

304

308

271

112

294

219

305

279

144

246

207

Net income (loss) attributable to noncontrolling interests, net of tax

-6

0

0

0

0

-1

-1

48

-1

131

0

0

-0

-1

-2

-1

-1

-2

53

-2

-2

-0

-0

8

-0

0

0

0

0

0

0

0

-0

-0

1

16

14

31

-141

1

2

0

1

2

2

1

Net income attributable to Biogen Inc.

1,399

1,439

1,545

1,494

1,408

946

1,444

866

1,172

-297

1,226

862

747

649

1,032

1,049

970

831

965

927

822

883

856

714

479

457

487

490

426

292

398

386

302

300

351

288

294

240

254

293

217

305

277

142

243

206

Net income per share:
Basic earnings per share attributable to Biogen Inc.

8.10

8.05

8.40

7.85

7.17

4.73

7.17

4.18

5.55

-1.40

5.80

4.07

3.47

3.01

4.72

4.79

4.44

3.78

4.16

3.94

3.50

3.74

3.63

3.02

2.03

1.93

2.06

2.07

1.80

1.24

1.68

1.62

1.26

1.23

1.45

1.19

1.22

0.99

1.06

1.13

0.80

1.07

0.96

0.49

0.85

0.71

Diluted earnings per share attributable to Biogen Inc.

8.08

8.03

8.39

7.85

7.15

4.71

7.15

4.18

5.54

-1.40

5.79

4.07

3.46

3.00

4.71

4.79

4.43

3.77

4.15

3.93

3.49

3.72

3.62

3.01

2.02

1.91

2.05

2.06

1.79

1.23

1.67

1.61

1.25

1.23

1.43

1.18

1.20

0.97

1.05

1.12

0.80

1.07

0.95

0.49

0.84

0.70

Weighted-average shares used in calculating:
Basic earnings per share attributable to Biogen Inc.

172

177

184

190

196

199

201

207

211

211

211

211

215

216

218

219

218

220

232

235

235

235

236

236

236

236

237

237

236

236

236

238

239

242

242

242

241

239

239

259

269

284

288

288

287

291

Diluted earnings per share attributable to Biogen Inc.

173

178

184

190

197

200

201

207

211

212

211

212

215

217

219

219

219

220

232

235

235

236

236

237

237

237

238

238

238

238

238

240

241

245

245

244

244

242

242

261

272

286

291

290

289

293

Product, net
Total revenues

2,904

2,924

2,894

2,880

2,680

2,825

2,780

2,757

2,523

2,712

2,622

2,639

2,380

2,502

2,539

2,466

2,309

2,425

2,391

2,198

2,172

2,286

2,117

2,056

1,742

1,607

1,453

1,385

1,095

1,074

1,039

1,076

975

996

975

956

907

909

876

859

824

826

801

790

733

758

Revenues from anti-CD20 therapeutic programs
Total revenues

520

600

595

576

517

534

511

490

443

415

406

397

340

318

317

349

329

333

337

337

330

304

290

303

296

269

303

288

264

280

287

284

284

257

266

216

256

257

257

306

254

256

283

275

278

298

Other
Total revenues

109

145

109

160

292

165

147

108

164

179

48

41

90

50

98

79

87

79

49

55

52

49

103

61

90

89

71

48

54

62

58

59

31

72

67

35

40

51

40

47

29

43

34

26

24

35